Consensus Milestone Pharmaceuticals Inc.

Equities

MIST

CA59935V1076

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.7 ^USD	0.00%		+0.59%	+1.80%

Apr. 08	Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients? Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting	CI
Mar. 28	Milestone Pharmaceuticals Resubmits Etripamil New Drug Application to FDA	MT

Evolution of the average Target Price on Milestone Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

b9987a7a8aa53b3e9f15c9c3.N4FEMYkm49t5vJBZiSyXTpw2lbxQjkOgFjdwfhtmVig.bt4CA85e2ukc7qMQvlrIAupDw4shu3H1R28FNmksJlpS5R0Fu2K36AnQ_w~a9ed172663ee7043c43c658e4652eedb

Analyst Recommendations on Milestone Pharmaceuticals Inc.

Piper Sandler Trims Price Target on Milestone Pharmaceuticals to $5 From $6, Keeps Overweight Rating	Mar. 05	MT
TD Cowen Cuts Price Target on Milestone Pharmaceuticals to $9 From $17, Maintains Outperform Rating	Dec. 27	MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $11 From $13, Maintains Outperform Rating	23-08-11	MT
Jefferies Downgrades Milestone Pharmaceuticals to Hold From Buy	23-06-20	MT
Oppenheimer Adjusts Milestone Pharmaceuticals' Price Target to $13 From $16, Keeps Outperform Rating	23-04-12	MT
Oppenheimer Adjusts Milestone Pharmaceuticals Price Target to $16 From $15, Maintains Outperform Rating	22-04-25	MT
Piper Sandler Lifts Milestone Pharmaceuticals to Overweight From Neutral, Price Target to $10 From $8	22-04-22	MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $14 From $17, Maintains Outperform Rating	21-05-18	MT
MILESTONE PHARMACEUTICALS : Oppenheimer Adjusts Milestone Pharmaceuticals PT to $17 From $18 Following Q4 Report, Maintains Outperform Rating	21-03-31	MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate	21-03-29	MT
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate	21-03-29	CI
MILESTONE PHARMACEUTICALS : HC Wainwright Starts Milestone Pharmaceuticals at Buy With $20 Price Target	21-03-05	MT
Milestone Pharmaceuticals : Enrolls First Patient in Phase 3 Study of Etripamil Nasal Spray for Rapid Heart Rate	20-11-18	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.7 USD

Average target price

10.5 USD

Spread / Average Target

+517.65%

High Price Target

25 USD

Spread / Highest target

+1,370.59%

Low Price Target

3 USD

Spread / Lowest Target

+76.47%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Milestone Pharmaceuticals Inc.

Piper Sandler
TD Cowen
Oppenheimer
Jefferies & Co.
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar